The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir.

The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir.
复制标题

DOI:
10.1128/mbio.02815-22
复制
发表时间:
2023-02-28
期刊:
影响因子:
6.4
通讯作者:
--
中科院分区:
生物学1区
文献类型:
--
作者:

文献摘要

参考文献

被引文献

相似文献

SARS-CoV-2主要蛋白酶(3CLpro)在病毒生命周期中具有不可或缺的作用,是治疗COVID-19的治疗靶点。需要确定3CL前体抑制剂选择耐药变体的潜力。因此,SARS-CoV-2在增加浓度的ALG-097161存在下体外传代,ALG-097161是在3CLpro药物发现计划的背景下设计的探针化合物。我们鉴定了3CLpro(L50 F E166 A L167 F)中的氨基酸取代组合,其与ALG-097161、Nirmatrelvir(PF-07321332)、PF-00835231和恩西曲韦的50%有效浓度(EC 50)值增加>20倍相关。虽然两个单一的取代(E166 A和L167 F)提供了低水平的抗性抑制剂在生化试验中,三重突变体的结果在最高水平的抗性(6×至72×)。所有取代都与酶促3CLpro活性的显著损失相关,表明病毒适应性降低。结构生物学分析表明,不同的取代减少了抑制剂/酶相互作用的数量,同时保持底物的结合。这些观察结果对于解释临床环境中对3CLpro抑制剂的耐药性发展非常重要。
The SARS-CoV-2 main protease (3CLpro) has an indispensable role in the viral life cycle and is a therapeutic target for the treatment of COVID-19. The potential of 3CLpro-inhibitors to select for drug-resistant variants needs to be established. Therefore, SARS-CoV-2 was passaged in vitro in the presence of increasing concentrations of ALG-097161, a probe compound designed in the context of a 3CLpro drug discovery program. We identified a combination of amino acid substitutions in 3CLpro (L50F E166A L167F) that is associated with a >20× increase in 50% effective concentration (EC50) values for ALG-097161, nirmatrelvir (PF-07321332), PF-00835231, and ensitrelvir. While two of the single substitutions (E166A and L167F) provide low-level resistance to the inhibitors in a biochemical assay, the triple mutant results in the highest levels of resistance (6× to 72×). All substitutions are associated with a significant loss of enzymatic 3CLpro activity, suggesting a reduction in viral fitness. Structural biology analysis indicates that the different substitutions reduce the number of inhibitor/enzyme interactions while the binding of the substrate is maintained. These observations will be important for the interpretation of resistance development to 3CLpro inhibitors in the clinical setting.
DOI: 10.1074/jbc.m115.651463
发表时间: 2015-08-07
期刊: The Journal of biological chemistry
影响因子: --
作者:
Tomar S;Johnston ML;St John SE;Osswald HL;Nyalapatla PR;Paul LN;Ghosh AK;Denison MR;Mesecar AD
通讯作者: Mesecar AD
DOI: 10.7554/elife.77433
发表时间: 2022-06-20
期刊: ELIFE
影响因子: 7.7
作者:
Flynn, Julia M.;Samant, Neha;Schneider-Nachum, Gily;Barkan, David T.;Yilmaz, Nese Kurt;Schiffer, Celia A.;Moquin, Stephanie A.;Dovala, Dustin;Bolon, Daniel N. A.
通讯作者: Bolon, Daniel N. A.
DOI: 10.1038/s41467-022-28354-0
发表时间: 2022-02-15
影响因子: 16.6
作者:
Abdelnabi R;Foo CS;Jochmans D;Vangeel L;De Jonghe S;Augustijns P;Mols R;Weynand B;Wattanakul T;Hoglund RM;Tarning J;Mowbray CE;Sjö P;Escudié F;Scandale I;Chatelain E;Neyts J
通讯作者: Neyts J
DOI: 10.1016/j.antiviral.2021.105158
发表时间: 2021-10
期刊: Antiviral research
影响因子: 7.6
作者:
通讯作者: --